Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07284459 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 89 → 92 locations
  2. Study sites: 89 to 91
  3. Trial sites expanded: 82 → 87 locations
  4. Study sites: 81 to 82
  5. Study sites: 80 to 81
  6. Trial sites expanded: 76 → 79 locations Trial sites expanded: 73 → 76 locations · Eligibility criteria expanded, about 9 words Show 2 more changesShow less
    • Trial sites expanded: 73 → 76 locations
    • Eligibility criteria expanded, about 9 words
  7. Study sites: 69 to 70v37
  8. Study sites: 68 to 69v36
  9. Trial sites expanded: 65 → 68 locationsv35
  10. Study sites: 64 to 65v34
  11. Trial sites expanded: 60 → 64 locationsv33
  12. Trial sites expanded: 57 → 60 locationsv32
  13. Study sites: 56 to 57v31
  14. Study sites: 54 to 56v30
  15. Study sites: 53 to 54v29
  16. Study sites: 52 to 53v28
  17. Study sites: 51 to 52v27
  18. Study sites: 50 to 51v26
  19. Study sites: 49 to 50v25
  20. Study sites: 48 to 49v24
  21. Trial sites expanded: 42 → 47 locationsv23
  22. Study sites: 42 to 47 Eligibility criteria expanded, about 10 words · Secondary endpoints: 6 to 7 · Study description revisedv22 Show 3 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 6 to 7
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  23. Trial sites expanded: 35 → 39 locationsv21
  24. Trial sites expanded: 32 → 35 locationsv20
  25. Trial sites expanded: 29 → 32 locationsv19
  26. Study sites: 32 to 35v18
  27. Study sites: 29 to 32v17
  28. Study sites: 28 to 29v16
  29. Study sites: 27 to 28v15
  30. Trial sites expanded: 22 → 25 locationsv14
  31. Study sites: 22 to 25v13
  32. Study sites: 21 to 22v12
  33. Study sites: 20 to 21v11
  34. Study sites: 19 to 20v10
  35. Study sites: 18 to 19v9
  36. Study sites: 17 to 18v8
  37. Study sites: 16 to 17v7
  38. Trial sites expanded: 11 → 14 locationsv6
  39. Study sites: 11 to 14v5
  40. Trial sites expanded: 2 → 11 locationsv4
  41. Study sites: 1 to 2 Start date changed from estimate of Dec 2025 to Jan 8, 2026v3 Show 1 more changeShow less
    • Start date changed from estimate of Dec 2025 to Jan 8, 2026
  42. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Secondary endpoints: 5 to 6v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Secondary endpoints: 5 to 6

    See this version in full on ClinicalTrials.gov ↗

  43. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Trial Details
NCT Number NCT07284459
Lead Sponsor Contineum Therapeutics
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 324 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov